TEL AVIV, Israel, Oct. 4, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today announced that SCS, its wholly owned subsidiary, is initiating procedures to conduct second phase clinical trials with our medical device, SkinScan 650. These trials come at the end of an upgrading program of SkinScan 650. We expect the results of the trials to show improved accuracy in diagnosing NMSC (Non Melanoma Skin Cancer).
The planned, second phase, clinical trials are based on the successfully conducted, first phase trials. The results of the first phase trials demonstrated a 92.4% accuracy in diagnosing non-melanoma skin cancer (NMSC). Those results are significantly higher than the 75% accuracy rate, achieved by an experienced dermatologist and 60% accuracy achieved by a general practitioner.
We expect the planned trials to show material improvement in the diagnostic capabilities. The second phase trials will be conducted in compliance with FDA protocol requirements. It is our intention to start the trials Mid January, 2011.
Following the second phase clinical trials, we intend to extend SkinScan 650's technical capabilities into the Infra Red range of the spectrum. Succeeding in this technological improvement coupled with our unique proprietary algorithms, will dramatically improve results in diagnosing both Melanoma and Non Melanoma Skin Cancers.
We expect the finalization of this stage, the Infra Red range, of development by mid 2011. This will enable us to introduce and revolutionize the entire approach to Skin Cancer Early detection and diagnosis.
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our medical device, SkinScan 650's state-of-the-art technology will enable physicians to improve their diagnostic abilities using SkinScan 650. This will replace current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and lower chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.
For more information on SCS, visit the company's new website at .
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
CONTACT: mBeach Software Inc. Col. Yossi Biderman, CEO firstname.lastname@example.org